Qiagen : FY review – Strong finish and positive outlook
>Q4 with strong finish - Qiagen’s Q4 revenues of $ 498m (-14.5% y-o-y) were 1% ahead of our and the consensus’ expectations. Revenues development at CER was -9%, while forex translated to a headwind of 450bp. COVID-19 related revenues were down 61% CER to $ 66m in the quarter. Correspondingly, non-COVID product groups were up 15% CER in the quarter, which we rate as positive. Adjusted EBIT of $ 135m (-32.3% y-o-y, margin 27.1%) was 3% below ODDO BHF’s estimate, but 1%...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.